The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management
Open accessAbstract
Disease Overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. Additional disease features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. Diagnosis: Bone marrow morphology is the primary basis for diagnosis. Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 World Health Organization classification system distinguishes “prefibrotic” from “overtly fibrotic” PMF; the former might mimic ET in its presentation. Furthermore, approximately 15% of patients with ET or PV might progress into a PMF‐like phenotype (post‐ET/PV MF) during their clinical course. Adverse Mutations: SRSF2, ASXL1, and U2AF1‐Q157 mutations predict inferior survival in PMF, independent of each other and other risk factors. RAS/CBL mutations predicted resistance to ruxolitinib therapy. Adverse Karyotype: Very high risk abnormalities include −7, inv (3), i(17q), +21, +19, 12p‐, and 11q‐. Risk Stratification: Two new prognostic systems for PMF have recently been introduced: GIPSS (genetically‐inspired prognostic scoring system) and MIPSS70+ version 2.0 (MIPSS v2; mutation‐ and karyotype‐enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype. MIPSS v2 includes, in addition, clinical risk factors. GIPSS features four and MIPSS v2 five risk categories. Risk‐adapted Therapy: Observation alone is advised for MIPSS v2 “low” and “very low” risk disease (estimated 10‐year survival 56%‐92%); allogeneic hematopoietic stem cell transplant (AHSCT) is the preferred treatment for “very high” and “high” risk disease (estimated 10‐year survival 0%‐13%); treatment‐requiring patients with intermediate‐risk disease (estimated 10‐year survival 30%) are best served by participating in clinical trials. In non‐transplant candidates, conventional treatment for anemia includes androgens, prednisone, thalidomide, and danazol; for symptomatic splenomegaly, hydroxyurea and ruxolitinib; and for constitutional symptoms, ruxolitinib. Fedratinib, another JAK2 inhibitor, has now been FDA‐approved for use in ruxolitinib failures. Splenectomy is considered for drug‐refractory splenomegaly and involved field radiotherapy for non‐hepatosplenic EMH and extremity bone pain. New Directions: A number of new agents, alone or in combination with ruxolitinib, are currently under investigation for MF treatment (ClinicalTrials.gov); preliminary results from some of these clinical trials were presented at the 2020 ASH annual meeting and highlighted in the current document.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationMyelofibrosis with Myeloid Metaplasia
Tefferi, A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004273421706 · Cited by 740
Self-citationBarbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., Orazi, A., & Tefferi, A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0054-y · Cited by 641
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Mudireddy, M., Mannarelli, C., Nicolosi, M., Pacilli, A., Pardanani, A., Rumi, E., Rosti, V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4886 · Cited by 552
Self-citationBarbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., Rodeghiero, F., d'Amore, E. S. G., Randi, M. L., Bertozzi, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5298 · Cited by 533
Self-citationon behalf of the COMFORT-II Investigators, Harrison, C. N., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Knoops, L., Cervantes, F., Jones, M. M., Sun, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.148 · Cited by 519
Barosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationPardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Self-citationCervantes, F., Vannucchi, A. M., Kiladjian, J.-J., Al-Ali, H. K., Sirulnik, A., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R. S., Passamonti, F., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485888 · Cited by 426
DiNardo, C. D., Rausch, C. R., Benton, C., Kadia, T., Jain, N., Pemmaraju, N., Daver, N., Covert, W., Marx, K. R., Mace, M., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25000 · Cited by 424
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5818 · Cited by 399
Kröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., et al. (2009) · Blood · doi:10.1182/blood-2009-07-234880 · Cited by 396
Mesa, R. A., Kiladjian, J.-J., Catalano, J. V., Devos, T., Egyed, M., Hellmann, A., McLornan, D., Shimoda, K., Winton, E. F., Deng, W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4418 · Cited by 387
Myeloproliferative Neoplasms: A Contemporary Review
Tefferi, A., & Pardanani, A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.89 · Cited by 342
Self-citationA Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1310523 · Cited by 325
Self-citationMesa, R. A., Vannucchi, A. M., Mead, A., Egyed, M., Szoke, A., Suvorov, A., Jakucs, J., Perkins, A., Prasad, R., Mayer, J., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30027-3 · Cited by 324
Harrison, C. N., Vannucchi, A. M., Platzbecker, U., Cervantes, F., Gupta, V., Lavie, D., Passamonti, F., Winton, E. F., Dong, H., Kawashima, J., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30237-5 · Cited by 321
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Tefferi, A., Lasho, T. L., Guglielmelli, P., Finke, C. M., Rotunno, G., Elala, Y., Pacilli, A., Hanson, C. A., Pancrazzi, A., Ketterling, R. P., et al. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000216 · Cited by 311
Self-citationGuglielmelli, P., Lasho, T. L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., et al. (2014) · Leukemia · doi:10.1038/leu.2014.76 · Cited by 310
Self-citationGIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Tefferi, A., Guglielmelli, P., Nicolosi, M., Mannelli, F., Mudireddy, M., Bartalucci, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0107-z · Cited by 306
Self-citationKoch, C. A., Li, C.-Y., Mesa, R. A., & Tefferi, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.10.1223 · Cited by 302
Self-citationPathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.9316 · Cited by 289
Self-citationTefferi, A., Mesa, R. A., Nagorney, D. M., Schroeder, G., & Silverstein, M. N. (2000) · Blood · doi:10.1182/blood.v95.7.2226 · Cited by 285
Self-citationMesa, R. A., Steensma, D. P., Pardanani, A., Li, C.-Y., Elliott, M., Kaufmann, S. H., Wiseman, G., Gray, L. A., Schroeder, G., Reeder, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2928 · Cited by 283
Self-citationTefferi, A., Guglielmelli, P., Lasho, T. L., Rotunno, G., Finke, C., Mannarelli, C., Belachew, A. A., Pancrazzi, A., Wassie, E. A., Ketterling, R. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.57 · Cited by 277
Self-citationLenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Self-citationTargeted deep sequencing in primary myelofibrosis
Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., Gangat, N., & Pardanani, A. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000208 · Cited by 219
Self-citationMyelodysplastic syndromes: Contemporary review and how we treat
Gangat, N., Patnaik, M. M., & Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24253 · Cited by 193
Self-citationKröger, N., Giorgino, T., Scott, B. L., Ditschkowski, M., Alchalby, H., Cervantes, F., Vannucchi, A., Cazzola, M., Morra, E., Zabelina, T., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608315 · Cited by 186
Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Rosti, V., Delaini, F., Maffioli, M., Fanelli, T., Pancrazzi, A., Pietra, D., et al. (2017) · Blood · doi:10.1182/blood-2017-01-761999 · Cited by 186
Mesa, R. A., Nagorney, D. S., Schwager, S., Allred, J., & Tefferi, A. (2006) · Cancer · doi:10.1002/cncr.22021 · Cited by 177
Self-citationMyeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24221 · Cited by 177
Self-citationJAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Tefferi, A. (2012) · Blood · doi:10.1182/blood-2011-11-395228 · Cited by 172
Self-citationRuxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Heine, A., Brossart, P., & Wolf, D. G. F. (2013) · Blood · doi:10.1182/blood-2013-10-531103 · Cited by 163
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Tefferi, A., Litzow, M. R., & Pardanani, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1109555 · Cited by 159
Self-citationTargeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T. L., Schneider, R. K., Breyfogle, L. J., Schultz, R. F., Gilles, L., Koppikar, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3995 · Cited by 157
Self-citationHarrison, C. N., Schaap, N. P., Vannucchi, A. M., Kiladjian, J., Jourdan, É., Silver, R. T., Schouten, H. C., Passamonti, F., Zweegman, S., Talpaz, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25777 · Cited by 155
Quintás‐Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D. A., Cortes, J. E., Ravandi, F., Garcia‐Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 154
Martínez‐Trillos, A., Gayà, A., Maffioli, M., Arellano‐Rodrigo, E., Calvo, X., Díaz‐Beyá, M., & Cervantes, F. (2010) · Annals of Hematology · doi:10.1007/s00277-010-1019-9 · Cited by 148
Shanavas, M., Popat, U., Michaelis, L. C., Fauble, V. D. S., McLornan, D. P., Klisovic, R. B., Mascarenhas, J. O., Tamari, R., Arcasoy, M. O., Davies, J. O. J., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.10.005 · Cited by 147
Barosi, G., Ambrosetti, A., Centra, A., Falcone, A. P., Finelli, C., Foa, P., Grossi, A., Guarnone, R., Rupoli, S., Luciano, L., et al. (1998) · PubMed · Cited by 132
Tefferi, A., Nicolosi, M., Mudireddy, M., Lasho, T. L., Gangat, N., Begna, K. H., Hanson, C. A., Ketterling, R. P., & Pardanani, A. D. (2018) · Leukemia · doi:10.1038/s41375-018-0018-z · Cited by 131
Self-citationOh, S. T., Talpaz, M., Gerds, A. T., Gupta, V. K., Verstovšek, S., Mesa, R. A., Miller, C. B., Rivera, C. E., Fleischman, A. G., Goel, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002662 · Cited by 130
Tefferi, A., Nicolosi, M., Mudireddy, M., Szuber, N., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., Pardanani, A. D., Gangat, N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24978 · Cited by 127
Self-citationThalidomide treatment in myelofibrosis with myeloid metaplasia
Elliott, M. A., Mesa, R. A., Li, C., Hook, C. C., Ansell, S. M., Levitt, R., Geyer, S. M., & Tefferi, A. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03443.x · Cited by 126
Self-citationTefferi, A., Lasho, T. L., Mesa, R. A., Pardanani, A. D., Ketterling, R. P., & Hanson, C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404711 · Cited by 124
Self-citationTargeted next-generation sequencing in blast phase myeloproliferative neoplasms
Lasho, T. L., Mudireddy, M., Finke, C. M., Hanson, C. A., Ketterling, R. P., Szuber, N., Begna, K. H., Patnaik, M. M., Gangat, N., Pardanani, A. D., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018015875 · Cited by 116
Self-citationStübig, T., Alchalby, H., Ditschkowski, M., Wolf, D. G. F., Wulf, G. G., Zabelina, T., Wolschke, C., Ayuk, F. A., & Kröger, N. M. (2014) · Leukemia · doi:10.1038/leu.2014.86 · Cited by 105
McLornan, D. P., Szydlo, R., Köster, L., Chalandon, Y., Robin, M., Wolschke, C., Beelen, D. W., Socié, G., Bornhäuser, M., Angelucci, E., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.034 · Cited by 104
Thalidomide therapy for myelofibrosis with myeloid metaplasia
Thomas, D. A., Giles, F. J., Albitar, M. X., Cortes, J. E., Verstovšek, S., Faderl, S. H., O'Brien, S. M., Garcia‐Manero, G., Keating, M. J., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21827 · Cited by 101
U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
Tefferi, A., Finke, C. M., Lasho, T. L., Hanson, C. A., Ketterling, R. P., Gangat, N., & Pardanani, A. D. (2018) · Leukemia · doi:10.1038/s41375-018-0078-0 · Cited by 100
Self-citationMyelofibrosis biology and contemporary management
Gangat, N., & Tefferi, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16576 · Cited by 94
Self-citationPrognostic impact of RAS-pathway mutations in patients with myelofibrosis
Santos, F. P. D. S., Getta, B. M., Masárová, L., Famulare, C. A., Schulman, J., Datoguia, T. S., Puga, R., Paiva, R. D. M. A., Arcila, M. E., Hamerschlak, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0603-9 · Cited by 91
Coltro, G., Rotunno, G., Mannelli, L., Mannarelli, C., Fiaccabrino, S., Romagnoli, S., Bartalucci, N., Ravenda, E., Gelli, E., Sant’Antonio, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002175 · Cited by 91
Self-citationRuxolitinib: a steroid sparing agent in chronic graft-versus-host disease
Khoury, H. J., Langston, A. A., Kota, V. K., Wilkinson, J. A., Pusic, I., Jillella, A., Bauer, S. L., Kim, A. S., Roberts, D., Al-Kadhimi, Z. S., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-017-0081-5 · Cited by 86
Polverelli, N., Mauff, K. A. L., Kröger, N. M., Robin, M., Beelen, D. W., Beauvais, D., Chevallier, P., Mohty, M., Passweg, J. R., Rubio, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26020 · Cited by 86
Gangat, N., Marinaccio, C., Swords, R. T., Watts, J. M., Gurbuxani, S. K., RADEMAKER, A. W., Fought, A. J., Frankfurt, O., Altman, J. K., Wen, Q. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1005 · Cited by 80
Self-citationPardanani, A. D., Gotlib, J. R., Roberts, A. W., Wadleigh, M., Sirhan, S., Kawashima, J., Maltzman, J., Shao, L., Gupta, V. K., & Tefferi, A. (2017) · Leukemia · doi:10.1038/leu.2017.330 · Cited by 76
Self-citationVallapureddy, R. R., Mudireddy, M., Penna, D., Lasho, T. L., Finke, C. M., Hanson, C. A., Ketterling, R. P., Begna, K. H., Gangat, N., Pardanani, A. D., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0175-y · Cited by 75
Self-citationAli, H., Aldoss, I. T., Yang, D., Mokhtari, S., Khaled, S. K., Aribi, A. M., Afkhami, M., Malki, M. M. A., Cao, T. M., Mei, M. G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026658 · Cited by 74
Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
Tefferi, A. (2012) · New England Journal of Medicine · doi:10.1056/nejme1115119 · Cited by 67
Self-citationChronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management
Patnaik, M. M., & Tefferi, A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24396 · Cited by 64
Self-citationBannow, B. S., Salit, R. B., Storer, B. E., Stevens, E. A., Wu, D., Yeung, C. C. S., Fang, M., Petersdorf, E. W., Linenberger, M. L., Woo, J., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.09.016 · Cited by 64
Momelotinib therapy for myelofibrosis: a 7-year follow-up
Tefferi, A., Barraco, D., Lasho, T. L., Shah, S. H., Begna, K. H., Al‐Kali, A., Hogan, W. J., Litzow, M. R., Hanson, C. A., Ketterling, R. P., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0067-6 · Cited by 59
Self-citationPieri, L., Paoli, C., Arena, U., Marra, F., Mori, F., Zucchini, M., Colagrande, S., Castellani, A., Masciulli, A., Rosti, V., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24614 · Cited by 56
A life‐threatening ruxolitinib discontinuation syndrome
Coltro, G., Mannelli, F., Guglielmelli, P., Pacilli, A., Bosi, A., & Vannucchi, A. M. (2017) · American Journal of Hematology · doi:10.1002/ajh.24775 · Cited by 51
Kadir, S. S. S. A., Christopeit, M., Wulf, G. G., Wagner, E. M., Bornhäuser, M., Schroeder, T. A., Crysandt, M. M., Mayer, K. T., Jonas, J., Stelljes, M., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13099 · Cited by 48
Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
Tefferi, A., Lasho, T. L., Finke, C. M., Gangat, N., Hanson, C. A., Ketterling, R. P., & Pardanani, A. D. (2017) · Leukemia · doi:10.1038/leu.2017.318 · Cited by 35
Self-citationDurrant, S., Nagler, A., Guglielmelli, P., Lavie, D., le Coutre, P., Gisslinger, H., Chuah, C. T. H., Maffioli, M., Bharathy, S., Dong, T., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209965 · Cited by 33
Tremblay, D. A., Feld, J., Dougherty, M., Czaplinska, T., Sanchez, G., Kremyanskaya, M., Bar‐Natan, M., Shih, A. H., Keyzner, A., & Mascarenhas, J. O. (2020) · Leukemia Research · doi:10.1016/j.leukres.2020.106456 · Cited by 30
Tsukamoto, Y., Kiyasu, J., Tsuda, M., Ikeda, M., Shiratsuchi, M., Ogawa, Y., & Yufu, Y. (2017) · Internal Medicine · doi:10.2169/internalmedicine.9165-17 · Cited by 26
Bossard, J., Beuscart, J., Robin, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26034 · Cited by 25
Hanif, A., Hari, P., Atallah, E. L., Carlson, K.-S., Pasquini, M. C., & Michaelis, L. C. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.295 · Cited by 22
Cited by
The interaction between ferroptosis and inflammatory signaling pathways
Chen, Y., Fang, Z.-M., Yi, X., Wei, X., & Jiang, D.-S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05716-0 · Cited by 567
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Self-citationVerstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0901 · Cited by 41
Metadata
- Authors
- Tefferi, A.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2020-12-02
- Volume
- 96
- Issue
- 1
- Pages
- 145-162
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3105658552
- Cited by
- 315
- References
- 80
- FWCI
- 20.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.